Weight Loss & Metabolic
Best Peptides for Liver Health, NAFLD & MASH: Evidence (2026)
An evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
NAFLD/MASLDMASH/NASHGLP-1 agonistsbiopsy RCT evidenceFDA-approved 2025
The quick verdict
For fatty liver, the strongest 'peptides' are the incretin and gut-hormone drugs — and unusually for this genre, they are proven in large, biopsy-confirmed human trials, with semaglutide now the first FDA-approved peptide for MASH.
- Best overall
- Semaglutide (GLP-1 agonist) — The only peptide with a Phase 3 biopsy-confirmed RCT (ESSENCE) and the first FDA-approved for noncirrhotic MASH with F2–F3 fibrosis — the reference standard.
- Best value
- Semaglutide (Wegovy) — As the only approved, prescribable option with Phase 3 histology data, it is the only agent that can be obtained and used legally through normal medical channels rather than trials or gray markets.
- Best for Maximum liver-fat reduction on imaging (research setting)
- Retatrutide (triple GIP/GLP-1/glucagon agonist) — Produced the largest liver-fat reduction of any agent (~86% by MRI-PDFF) — but only on imaging, with no biopsy or fibrosis data, and it remains investigational.
How we evaluated
Peptides were ranked strictly by the strength of published human evidence for fatty liver disease specifically — favoring biopsy-confirmed randomized controlled trials over imaging surrogates, and human data over preclinical or anecdotal claims. Regulatory status (FDA approval, Breakthrough/Fast Track, investigational) and honesty about endpoints (histology vs MRI-PDFF; general population vs HIV-only) were weighted heavily. This is an editorial synthesis of the literature, not a protocol or sourcing guide.
- Human trial quality. Phase and design: Phase 3 biopsy RCT > Phase 2 biopsy RCT > imaging-only sub-study > HIV-only or preclinical.
- Endpoint rigor. Biopsy-confirmed MASH resolution and fibrosis improvement outrank MRI-PDFF liver-fat reduction, which is a surrogate.
- Regulatory status. FDA approval for MASH, then Breakthrough/Fast Track designation, then investigational-only.
- Population generalizability. Effects proven in the general fatty-liver population rank above HIV-only or narrow-subgroup data.
- Mechanistic fit & honesty. Alignment with the metabolic/insulin-resistance root cause, and transparency where a drug's mechanism (e.g. diabetogenic GH) cuts against it.
Rating scale: 1–5 stars reflecting strength of human evidence for fatty liver disease specifically, not potency or popularity.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Semaglutide (GLP-1 receptor agonist) | A | 5.0 | Adults with biopsy-confirmed noncirrhotic MASH and F2–F3 fibrosis seeking an approved, evidence-based option | Prescription (Wegovy); varies by pharmacy/insurance |
| 2 | Tirzepatide (GIP/GLP-1 dual agonist) | A | 4.5 | Clinicians and patients tracking the strongest near-approval MASH candidate with existing metabolic indications | Prescription (off-label for MASH); varies by pharmacy/insurance |
| 3 | Survodutide (glucagon/GLP-1 dual agonist) | B | 4.0 | Readers following the leading glucagon/GLP-1 dual-agonist MASH candidate through its Phase 3 readout | Investigational — clinical trials only |
| 4 | Retatrutide (GIP/GLP-1/glucagon triple agonist) | B | 3.5 | Following the most potent triple-agonist through Phase 3, where real histologic endpoints will be tested | Investigational — clinical trials only |
| 5 | Tesamorelin (GHRH analog) | B | 2.5 | Understanding the growth-hormone lever on liver fat and its limits outside HIV-associated NAFLD | Prescription (HIV lipodystrophy only); off-label/unproven for NAFLD |
Semaglutide (GLP-1 receptor agonist)
The only peptide FDA-approved for MASH — Phase 3 biopsy proof
Semaglutide is an engineered once-weekly subcutaneous GLP-1 analog (marketed as Wegovy and Ozempic) and one of the most rigorously human-tested peptide drugs in medicine. For fatty liver it is the reference standard: the Phase 3 ESSENCE trial (NCT04822181; n=1,197; biopsy-confirmed MASH with F2–F3 fibrosis) reported at its Week-72 interim analysis that once-weekly semaglutide 2.4 mg resolved steatohepatitis without worsening fibrosis in 62.9% of patients versus 34.3% on placebo, and improved fibrosis without worsening MASH in 36.8% versus 22.4%, with a mean weight change of −10.5% versus −2.0%. On that basis the FDA approved Wegovy in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis — the first GLP-1 ever indicated for liver disease, and only the second MASH drug after resmetirom. Its liver benefit is largely, though not entirely, weight-mediated: the drug reduces caloric intake, visceral fat and lipotoxic load on the liver. It is the only peptide here combining Phase 3 histology with a liver-specific approval, which is why it ranks first.
Strengths
- Phase 3, biopsy-confirmed RCT (ESSENCE) — the highest evidence tier for this condition
- First and only peptide FDA-approved for MASH (noncirrhotic, F2–F3, August 2025)
- Prescribable through normal medical channels; well-characterized long-term safety profile
- Large, robust effect on both steatohepatitis resolution and fibrosis improvement
Weaknesses
- Boxed warning for rodent thyroid C-cell tumors; contraindicated with medullary thyroid carcinoma or MEN 2 history
- Common GI effects (nausea, diarrhea); benefit is largely weight-mediated and tracks adherence; does not reverse cirrhosis
- Best for
- Adults with biopsy-confirmed noncirrhotic MASH and F2–F3 fibrosis seeking an approved, evidence-based option
- Pricing
- Prescription (Wegovy); varies by pharmacy/insurance
Tirzepatide (GIP/GLP-1 dual agonist)
Strong Phase 2 biopsy data, clear dose-response — not yet approved for MASH
Tirzepatide is a once-weekly dual incretin (marketed as Mounjaro and Zepbound), FDA-approved for type 2 diabetes and obesity but not yet for MASH. Its liver evidence is strong: the Phase 2 SYNERGY-NASH trial (NCT04166773; n=190; biopsy-confirmed MASH with F2–F3 fibrosis; 130 sites across 10 countries) showed MASH resolution without worsening fibrosis in 51.8%, 62.8% and 73.3% of patients on 5, 10 and 15 mg respectively, versus 13.2% on placebo at 52 weeks. Fibrosis improvement (at least one stage, no worsening MASH) reached 51–55% versus 30% on placebo, alongside improvements in ALT, AST, GGT and liver fat. The dual mechanism — adding GIP-receptor co-agonism to GLP-1 — amplifies weight loss and insulin sensitization, producing a clean dose-dependent histologic response that numerically rivals or exceeds semaglutide. What holds it at rank 2 is that this is Phase 2, not Phase 3, and it carries no FDA MASH indication as of 2026, with the manufacturer reportedly in regulatory discussions. Its safety profile mirrors other incretins.
Strengths
- Biopsy-confirmed Phase 2 RCT (SYNERGY-NASH) with a clear, clean dose-response
- Histologic MASH-resolution rates numerically rivaling or exceeding semaglutide at higher doses
- Already FDA-approved and widely used for T2D/obesity, so real-world safety is well-characterized
- Improved liver enzymes (ALT/AST/GGT) and liver fat alongside histology
Weaknesses
- No FDA MASH indication yet — the liver data are Phase 2, not Phase 3
- Same thyroid C-cell boxed warning and MTC/MEN-2 contraindication; GI adverse effects common
- Best for
- Clinicians and patients tracking the strongest near-approval MASH candidate with existing metabolic indications
- Pricing
- Prescription (off-label for MASH); varies by pharmacy/insurance
Survodutide (glucagon/GLP-1 dual agonist)
Positive Phase 2 biopsy data + FDA Breakthrough Therapy — still investigational
Survodutide (BI 456906; Boehringer Ingelheim/Zealand Pharma) is an investigational once-weekly dual glucagon-receptor/GLP-1-receptor agonist, with the glucagon arm specifically intended to mobilize hepatic lipid. Its Phase 2 trial (n=293; biopsy-confirmed MASH, F1–F3, liver fat at least 8%; 48 weeks; doses of 2.4/4.8/6.0 mg versus placebo) met its primary endpoint: improvement in MASH without worsening fibrosis in 47%, 62% and 43% of patients versus 14% on placebo. A liver-fat reduction of at least 30% was achieved by 63%, 67% and 57% versus 14%, and fibrosis improved (at least one stage) in 34%, 36% and 34% versus 22%. The 4.8 mg dose performed best, suggesting a quadratic dose-response. Mechanistically, glucagon-receptor agonism increases hepatic fatty-acid oxidation and reduces de novo lipogenesis, a liver-directed lever partly independent of caloric restriction. Survodutide holds FDA Breakthrough Therapy and Fast Track designations for noncirrhotic MASH (October 2024), plus EMA PRIME and China NMPA Breakthrough status, with Phase 3 LIVERAGE and LIVERAGE-Cirrhosis underway. But it has no Phase 3 outcome data and no approval yet, and is legally available only through clinical trials — so its overall evidence sits below the two approved or near-approved incretins.
Strengths
- Biopsy-confirmed Phase 2 RCT meeting its primary MASH-improvement endpoint
- Liver-directed glucagon mechanism (increased fatty-acid oxidation, reduced lipogenesis) beyond pure GLP-1 weight effects
- FDA Breakthrough Therapy and Fast Track plus EMA PRIME designations; two Phase 3 trials underway
- Fibrosis improvement demonstrated alongside MASH resolution
Weaknesses
- Investigational — no Phase 3 outcome data, no FDA approval, and not legally available outside trials
- Dose-related GI adverse events were the main tolerability limit; long-term safety awaits Phase 3
- Best for
- Readers following the leading glucagon/GLP-1 dual-agonist MASH candidate through its Phase 3 readout
- Pricing
- Investigational — clinical trials only
Retatrutide (GIP/GLP-1/glucagon triple agonist)
Biggest liver-fat drop of all (~86%) — but on imaging, not biopsy
Retatrutide (LY3437943; Eli Lilly) is an investigational once-weekly triple receptor agonist with roughly a 6-day half-life — arguably the most potent metabolic peptide in development. In a Phase 2a MASLD sub-study (n=98 with baseline liver fat at least 10%, drawn from the obesity Phase 2) treatment for 24–48 weeks produced dose-dependent liver-fat reductions up to about 86% by MRI-PDFF, with at least a 70% relative liver-fat reduction in at least 80% of those on the two highest doses, and steatosis resolution (under 5% liver fat) in roughly 85–90% at the top doses by 48 weeks. The cell-death marker K-18 fell up to ~49.6% and the fibrogenesis marker pro-C3 up to ~26.4%, with no hepatotoxicity signal. These are the largest liver-fat reductions recorded for any agent here — driven by the added glucagon lever on top of GIP and GLP-1. Yet the ranking is deliberately restrained: every one of those numbers comes from imaging in a small sub-study, with no liver biopsy, so retatrutide has no histologic MASH-resolution or fibrosis data. Liver-fat reduction is a necessary but not sufficient surrogate for MASH benefit, which is exactly what the Phase 3 program (with histology) is built to test. It remains investigational and not legally available outside trials — hence Grade B despite the biggest headline numbers.
Strengths
- Largest liver-fat reduction of any agent (~86% by MRI-PDFF); ~85–90% steatosis resolution at top doses
- Falls in cell-death (K-18) and fibrogenesis (pro-C3) markers with no hepatotoxicity signal
- Triple mechanism adds a liver-directed glucagon lever plus strong visceral-fat and insulin-sensitivity gains
Weaknesses
- No biopsy data — all endpoints are MRI-PDFF imaging surrogates in a small (n=98) sub-study; no MASH-resolution or fibrosis proof
- Investigational — not FDA-approved, not legally available outside trials; dose-dependent heart-rate increase noted
- Best for
- Following the most potent triple-agonist through Phase 3, where real histologic endpoints will be tested
- Pricing
- Investigational — clinical trials only
Source: Sanyal et al., Retatrutide Phase 2a MASLD sub-study, Nature Medicine 2024
Tesamorelin (GHRH analog)
A genuine liver RCT — but only in HIV, and diabetogenic
Tesamorelin (EGRIFTA / EGRIFTA SV / EGRIFTA WR) is a growth-hormone-releasing hormone (GHRH) analog that augments endogenous GH and IGF-1. It is FDA-approved only for excess visceral abdominal fat in HIV-associated lipodystrophy — not for NAFLD in any population. It earns a spot here because it has a genuine, if narrow, liver RCT: the pivotal trial (NCT02196831; n=61, all with HIV and hepatic fat fraction at least 5%; tesamorelin 2 mg/day versus placebo over 12 months) reduced liver fat by an absolute −4.1% and about 37% relative, returned 35% versus 4% of patients to liver fat under 5%, and slowed fibrosis progression (progression in 10.5% versus 37.5%). Follow-up transcriptomic work showed downregulation of hepatic inflammation and pro-fibrotic genes (VEGFA, TGFB1). The problem is generalizability and mechanism: this is a single small trial in people with HIV — a population with distinct, more aggressive NAFLD — with a modest effect size and no general-population efficacy data. A non-HIV Phase 2 was registered and a Phase 3 announced, but the program has stalled seeking a partner, so no non-HIV results exist. It is also the only agent here whose GH mechanism is diabetogenic, a poor fit for the insulin resistance underlying most fatty liver, and it is WADA-prohibited at all times.
Strengths
- A genuine randomized, placebo-controlled liver trial with reduced liver fat and slowed fibrosis progression
- Mechanistic follow-up showing downregulated hepatic inflammatory and pro-fibrotic gene expression
- FDA-approved (for HIV lipodystrophy), so its general safety profile is well-characterized
Weaknesses
- The only liver RCT is HIV-only (n=61) with a modest effect; no general-population efficacy data exist and the program has stalled
- GH mechanism is diabetogenic (glucose elevation) — cuts against the insulin resistance driving most fatty liver; WADA-prohibited at all times; off-label for NAFLD
- Best for
- Understanding the growth-hormone lever on liver fat and its limits outside HIV-associated NAFLD
- Pricing
- Prescription (HIV lipodystrophy only); off-label/unproven for NAFLD
Source: Stanley et al., Tesamorelin NAFLD in HIV RCT, Lancet HIV 2019
Frequently asked
What is the single best-evidenced peptide for fatty liver disease in 2026?
Semaglutide. It is the only peptide with a Phase 3, biopsy-confirmed randomized controlled trial for the condition and the only one FDA-approved for MASH. In the ESSENCE trial, once-weekly semaglutide 2.4 mg resolved steatohepatitis without worsening fibrosis in 62.9% of patients versus 34.3% on placebo, and improved fibrosis in 36.8% versus 22.4%, at 72 weeks. On that basis the FDA approved Wegovy in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced (F2–F3) fibrosis — the first GLP-1 ever indicated for liver disease. No other peptide currently combines Phase 3 histology data with a liver-specific approval.
Retatrutide cut liver fat by ~86% — isn't that the best drug?
It produced the largest liver-fat reduction of any agent, but the endpoint matters. That ~86% figure comes from MRI-PDFF imaging in a small Phase 2a sub-study of 98 people, with roughly 85–90% achieving steatosis resolution at the top doses. Retatrutide has no biopsy data on steatohepatitis resolution or fibrosis improvement, and it remains investigational — not FDA-approved and not legally available outside trials. Liver-fat percentage is a surrogate marker, not a histologic cure; reducing fat on a scan is necessary but not sufficient to prove MASH or fibrosis benefit. The Phase 3 program is designed to test those real endpoints, so retatrutide is graded B, not A.
Does tesamorelin work for fatty liver in people without HIV?
There is no published evidence that it does. Tesamorelin's only liver randomized controlled trial enrolled 61 people with HIV-associated NAFLD, where it reduced liver fat about 37% relative and slowed fibrosis progression over 12 months. That is a real result, but it is in a distinct population with more aggressive fatty-liver biology. A non-HIV general-population trial has not produced results, and the program has stalled seeking a development partner. Tesamorelin is FDA-approved only for excess visceral fat in HIV lipodystrophy, not for NAFLD in anyone. Its growth-hormone mechanism is also diabetogenic, which cuts against the insulin resistance that drives most fatty liver.
What about BPC-157 or other research peptides for liver health?
BPC-157's hepatoprotective evidence is entirely preclinical — rat models of carbon-tetrachloride toxicity, bile-duct ligation, alcohol and ischemia-reperfusion. There are no completed human clinical trials for any indication, let alone NAFLD or MASH, so it is Grade C at best and unproven for human liver disease despite heavy 'gut-liver detox' marketing. Other peptides sometimes promoted for liver, such as TB-500 (thymosin-β4) and MOTS-c, have no qualifying human efficacy trials for fatty liver either; their claims rest on mechanism or animal data. For fatty liver specifically, the peptides that actually work in humans are the incretin and gut-hormone drugs — not obscure research compounds.
Can these peptides reverse cirrhosis?
No established evidence supports that. The semaglutide approval and the leading survodutide and tirzepatide trials all target noncirrhotic MASH, generally F2–F3 fibrosis. Efficacy in compensated cirrhosis is still under investigation — for example the dedicated LIVERAGE-Cirrhosis study of survodutide — and has not been established. These agents can resolve steatohepatitis and improve earlier-stage fibrosis in trials, but that is different from undoing the architectural scarring of cirrhosis. Any marketing that claims a GLP-1 or dual agonist reverses cirrhosis outruns the data. Established cirrhosis remains a serious condition requiring specialist hepatology care.
How do these peptides actually improve the liver?
Most of the benefit is metabolic and weight-mediated. GLP-1 agonism (semaglutide) drives substantial weight and visceral-fat loss, cuts caloric intake and improves insulin sensitivity, which lowers the fat delivered to the liver and lets steatohepatitis resolve. Adding GIP (tirzepatide) amplifies that metabolic effect. Adding glucagon (survodutide, retatrutide) adds a more liver-directed mechanism: glucagon-receptor agonism increases hepatic fatty-acid oxidation and reduces de novo lipogenesis, which is why dual and triple agonists can clear liver fat especially aggressively. From a root-cause view, all of these are powerful levers layered on top of the diet, alcohol and metabolic drivers of fatty liver — not a substitute for addressing them.